Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup

The survival of patients with myelodysplastic syndromes is strongly affected by chromosomal abnormalities. Patients with an isolated del(5q31) have a favourable prognosis that worsens with the addition of another chromosomal abnormality. It has been reported that both patients with isolated del(5q31...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of hematology 2005-09, Vol.84 (9), p.569-571
Hauptverfasser: Giagounidis, A A N, Germing, U, Strupp, C, Hildebrandt, B, Heinsch, M, Aul, C
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 571
container_issue 9
container_start_page 569
container_title Annals of hematology
container_volume 84
creator Giagounidis, A A N
Germing, U
Strupp, C
Hildebrandt, B
Heinsch, M
Aul, C
description The survival of patients with myelodysplastic syndromes is strongly affected by chromosomal abnormalities. Patients with an isolated del(5q31) have a favourable prognosis that worsens with the addition of another chromosomal abnormality. It has been reported that both patients with isolated del(5q31) and those with one single additional chromosomal abnormality achieve hematological and cytogenetic remissions with lenalidomide therapy. Whether this translates into improved overall survival of the patient population is unclear. We analysed data of 25 patients with myelodysplastic syndrome and complex chromosomal abnormalities including del(5q31) and show that their median survival is between 7 and 8 months, irrespective of the medullary blast count. Furthermore, we present data of a patient with complex karyotypic anomalies inclusive of del(5q31) treated with lenalidomide who achieved complete cytogenetic remission. This cytogenetic remission was diagnosed after 6 months, and the hematological response is ongoing at 9 months of therapy at a dose of 5 mg p.o. daily. We conclude that lenalidomide has the potential to induce sustained hematological and cytogenetic remissions in the poor prognosis MDS subgroup of del(5q31) patients with complex chromosomal anomalies and that this is likely to improve overall survival.
doi_str_mv 10.1007/s00277-005-1054-0
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68440675</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2085621631</sourcerecordid><originalsourceid>FETCH-LOGICAL-c351t-4961dfdec751970d4249a8e044664a6276a6105d16c5903afdf86181567776533</originalsourceid><addsrcrecordid>eNpdkUtLxDAYRYMoOj5-gBsJLkQX1S9tXl2Kb1AU1HXINOkYbZuatOjgnzc6A4JZJBDOd8PNQWiXwDEBECcRIBciA2AZAUYzWEETQos8AybpKppAWZQZS2sDbcb4CkBySfN1tEGYLImUYoK-HoKfdT66iH2Nez042w0Rf7jhBRvbHLL3I3x3_oh1Z3Dl276xn_hNh7kf5r39vR1eLO59jG7aWBx82lJQYzvdOONbZyx2XYLSA8t0HMfpLPix30ZrtW6i3VmeW-j58uLp7Dq7vb-6OTu9zaqCkSGjJSemNrYSjJQCDM1pqaUFSjmnmueCa57qG8IrVkKha1NLTiRhXAjBWVFsoYNFbh_8-2jjoFoXK9s0urN-jIpLSoELlsD9f-CrH0NqkhhSlLkUnCeILKAqpNbB1qoPrk1fogioHy1qoUUlLepHi4I0s7cMHqetNX8TSw_FNwTeh3s</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>613928766</pqid></control><display><type>article</type><title>Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Giagounidis, A A N ; Germing, U ; Strupp, C ; Hildebrandt, B ; Heinsch, M ; Aul, C</creator><creatorcontrib>Giagounidis, A A N ; Germing, U ; Strupp, C ; Hildebrandt, B ; Heinsch, M ; Aul, C</creatorcontrib><description>The survival of patients with myelodysplastic syndromes is strongly affected by chromosomal abnormalities. Patients with an isolated del(5q31) have a favourable prognosis that worsens with the addition of another chromosomal abnormality. It has been reported that both patients with isolated del(5q31) and those with one single additional chromosomal abnormality achieve hematological and cytogenetic remissions with lenalidomide therapy. Whether this translates into improved overall survival of the patient population is unclear. We analysed data of 25 patients with myelodysplastic syndrome and complex chromosomal abnormalities including del(5q31) and show that their median survival is between 7 and 8 months, irrespective of the medullary blast count. Furthermore, we present data of a patient with complex karyotypic anomalies inclusive of del(5q31) treated with lenalidomide who achieved complete cytogenetic remission. This cytogenetic remission was diagnosed after 6 months, and the hematological response is ongoing at 9 months of therapy at a dose of 5 mg p.o. daily. We conclude that lenalidomide has the potential to induce sustained hematological and cytogenetic remissions in the poor prognosis MDS subgroup of del(5q31) patients with complex chromosomal anomalies and that this is likely to improve overall survival.</description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-005-1054-0</identifier><identifier>PMID: 15891887</identifier><language>eng</language><publisher>Germany: Springer Nature B.V</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Chromosome Aberrations ; Chromosome Deletion ; Chromosomes, Human, Pair 5 ; Humans ; Karyotyping ; Middle Aged ; Myelodysplastic Syndromes - drug therapy ; Myelodysplastic Syndromes - genetics ; Myelodysplastic Syndromes - mortality ; Prognosis ; Remission Induction ; Survival Rate ; Thalidomide - analogs &amp; derivatives ; Thalidomide - therapeutic use</subject><ispartof>Annals of hematology, 2005-09, Vol.84 (9), p.569-571</ispartof><rights>Springer-Verlag 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c351t-4961dfdec751970d4249a8e044664a6276a6105d16c5903afdf86181567776533</citedby><cites>FETCH-LOGICAL-c351t-4961dfdec751970d4249a8e044664a6276a6105d16c5903afdf86181567776533</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15891887$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Giagounidis, A A N</creatorcontrib><creatorcontrib>Germing, U</creatorcontrib><creatorcontrib>Strupp, C</creatorcontrib><creatorcontrib>Hildebrandt, B</creatorcontrib><creatorcontrib>Heinsch, M</creatorcontrib><creatorcontrib>Aul, C</creatorcontrib><title>Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><description>The survival of patients with myelodysplastic syndromes is strongly affected by chromosomal abnormalities. Patients with an isolated del(5q31) have a favourable prognosis that worsens with the addition of another chromosomal abnormality. It has been reported that both patients with isolated del(5q31) and those with one single additional chromosomal abnormality achieve hematological and cytogenetic remissions with lenalidomide therapy. Whether this translates into improved overall survival of the patient population is unclear. We analysed data of 25 patients with myelodysplastic syndrome and complex chromosomal abnormalities including del(5q31) and show that their median survival is between 7 and 8 months, irrespective of the medullary blast count. Furthermore, we present data of a patient with complex karyotypic anomalies inclusive of del(5q31) treated with lenalidomide who achieved complete cytogenetic remission. This cytogenetic remission was diagnosed after 6 months, and the hematological response is ongoing at 9 months of therapy at a dose of 5 mg p.o. daily. We conclude that lenalidomide has the potential to induce sustained hematological and cytogenetic remissions in the poor prognosis MDS subgroup of del(5q31) patients with complex chromosomal anomalies and that this is likely to improve overall survival.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Chromosome Aberrations</subject><subject>Chromosome Deletion</subject><subject>Chromosomes, Human, Pair 5</subject><subject>Humans</subject><subject>Karyotyping</subject><subject>Middle Aged</subject><subject>Myelodysplastic Syndromes - drug therapy</subject><subject>Myelodysplastic Syndromes - genetics</subject><subject>Myelodysplastic Syndromes - mortality</subject><subject>Prognosis</subject><subject>Remission Induction</subject><subject>Survival Rate</subject><subject>Thalidomide - analogs &amp; derivatives</subject><subject>Thalidomide - therapeutic use</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkUtLxDAYRYMoOj5-gBsJLkQX1S9tXl2Kb1AU1HXINOkYbZuatOjgnzc6A4JZJBDOd8PNQWiXwDEBECcRIBciA2AZAUYzWEETQos8AybpKppAWZQZS2sDbcb4CkBySfN1tEGYLImUYoK-HoKfdT66iH2Nez042w0Rf7jhBRvbHLL3I3x3_oh1Z3Dl276xn_hNh7kf5r39vR1eLO59jG7aWBx82lJQYzvdOONbZyx2XYLSA8t0HMfpLPix30ZrtW6i3VmeW-j58uLp7Dq7vb-6OTu9zaqCkSGjJSemNrYSjJQCDM1pqaUFSjmnmueCa57qG8IrVkKha1NLTiRhXAjBWVFsoYNFbh_8-2jjoFoXK9s0urN-jIpLSoELlsD9f-CrH0NqkhhSlLkUnCeILKAqpNbB1qoPrk1fogioHy1qoUUlLepHi4I0s7cMHqetNX8TSw_FNwTeh3s</recordid><startdate>20050901</startdate><enddate>20050901</enddate><creator>Giagounidis, A A N</creator><creator>Germing, U</creator><creator>Strupp, C</creator><creator>Hildebrandt, B</creator><creator>Heinsch, M</creator><creator>Aul, C</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20050901</creationdate><title>Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup</title><author>Giagounidis, A A N ; Germing, U ; Strupp, C ; Hildebrandt, B ; Heinsch, M ; Aul, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c351t-4961dfdec751970d4249a8e044664a6276a6105d16c5903afdf86181567776533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Chromosome Aberrations</topic><topic>Chromosome Deletion</topic><topic>Chromosomes, Human, Pair 5</topic><topic>Humans</topic><topic>Karyotyping</topic><topic>Middle Aged</topic><topic>Myelodysplastic Syndromes - drug therapy</topic><topic>Myelodysplastic Syndromes - genetics</topic><topic>Myelodysplastic Syndromes - mortality</topic><topic>Prognosis</topic><topic>Remission Induction</topic><topic>Survival Rate</topic><topic>Thalidomide - analogs &amp; derivatives</topic><topic>Thalidomide - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Giagounidis, A A N</creatorcontrib><creatorcontrib>Germing, U</creatorcontrib><creatorcontrib>Strupp, C</creatorcontrib><creatorcontrib>Hildebrandt, B</creatorcontrib><creatorcontrib>Heinsch, M</creatorcontrib><creatorcontrib>Aul, C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Giagounidis, A A N</au><au>Germing, U</au><au>Strupp, C</au><au>Hildebrandt, B</au><au>Heinsch, M</au><au>Aul, C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup</atitle><jtitle>Annals of hematology</jtitle><addtitle>Ann Hematol</addtitle><date>2005-09-01</date><risdate>2005</risdate><volume>84</volume><issue>9</issue><spage>569</spage><epage>571</epage><pages>569-571</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract>The survival of patients with myelodysplastic syndromes is strongly affected by chromosomal abnormalities. Patients with an isolated del(5q31) have a favourable prognosis that worsens with the addition of another chromosomal abnormality. It has been reported that both patients with isolated del(5q31) and those with one single additional chromosomal abnormality achieve hematological and cytogenetic remissions with lenalidomide therapy. Whether this translates into improved overall survival of the patient population is unclear. We analysed data of 25 patients with myelodysplastic syndrome and complex chromosomal abnormalities including del(5q31) and show that their median survival is between 7 and 8 months, irrespective of the medullary blast count. Furthermore, we present data of a patient with complex karyotypic anomalies inclusive of del(5q31) treated with lenalidomide who achieved complete cytogenetic remission. This cytogenetic remission was diagnosed after 6 months, and the hematological response is ongoing at 9 months of therapy at a dose of 5 mg p.o. daily. We conclude that lenalidomide has the potential to induce sustained hematological and cytogenetic remissions in the poor prognosis MDS subgroup of del(5q31) patients with complex chromosomal anomalies and that this is likely to improve overall survival.</abstract><cop>Germany</cop><pub>Springer Nature B.V</pub><pmid>15891887</pmid><doi>10.1007/s00277-005-1054-0</doi><tpages>3</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0939-5555
ispartof Annals of hematology, 2005-09, Vol.84 (9), p.569-571
issn 0939-5555
1432-0584
language eng
recordid cdi_proquest_miscellaneous_68440675
source MEDLINE; SpringerNature Journals
subjects Adult
Aged
Aged, 80 and over
Chromosome Aberrations
Chromosome Deletion
Chromosomes, Human, Pair 5
Humans
Karyotyping
Middle Aged
Myelodysplastic Syndromes - drug therapy
Myelodysplastic Syndromes - genetics
Myelodysplastic Syndromes - mortality
Prognosis
Remission Induction
Survival Rate
Thalidomide - analogs & derivatives
Thalidomide - therapeutic use
title Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T14%3A16%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognosis%20of%20patients%20with%20del(5q)%20MDS%20and%20complex%20karyotype%20and%20the%20possible%20role%20of%20lenalidomide%20in%20this%20patient%20subgroup&rft.jtitle=Annals%20of%20hematology&rft.au=Giagounidis,%20A%20A%20N&rft.date=2005-09-01&rft.volume=84&rft.issue=9&rft.spage=569&rft.epage=571&rft.pages=569-571&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-005-1054-0&rft_dat=%3Cproquest_cross%3E2085621631%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=613928766&rft_id=info:pmid/15891887&rfr_iscdi=true